Wu Songlin, Li Xiaoyan, Zhang Hongming
Department of Geriatrics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Department of Cardiology, Jinan Military General Hospital, Jinan, Shandong 250031, P.R. China.
Exp Ther Med. 2014 May;7(5):1349-1353. doi: 10.3892/etm.2014.1582. Epub 2014 Feb 24.
The aim of the present study was to examine the effect of metformin on endothelial function in patients with type 2 diabetes mellitus (T2DM). In total, 93 patients with T2DM and dissatisfactory glycemic control were randomly assigned to the metformin and pioglitazone groups and changes in vascular endothelial function were subsequently observed. Blood sugar levels and the insulin resistance (IR) index of the patients prior to treatment were lower than those following 12 months of treatment. In addition, fasting and postprandial insulin levels and the insulin function index were higher compared with those obtained following 12 months of treatment (P<0.05). Following 12 months of treatment, the body mass index (BMI) in the metformin group was lower than that in the pioglitazone group (P<0.05). Vascular endothelial function had improved in the groups following 12 months of treatment, when compared with the levels prior to treatment (P<0.05). Following 12 months of treatment, endothelial function in the metformin group had improved markedly compared with that in the pioglitazone group (P<0.05). Therefore, the administration of metformin and pioglitazone in patients with T2DM may improve insulin function, reduce the role of IR and improve endothelial function. Metformin is more successful than pioglitazone in reducing BMI and improving endothelial function.
本研究的目的是探讨二甲双胍对2型糖尿病（T2DM）患者内皮功能的影响。总共93例血糖控制不佳的T2DM患者被随机分为二甲双胍组和吡格列酮组，随后观察血管内皮功能的变化。患者治疗前的血糖水平和胰岛素抵抗（IR）指数低于治疗12个月后的水平。此外，与治疗12个月后的水平相比，空腹和餐后胰岛素水平及胰岛素功能指数更高（P<0.05）。治疗12个月后，二甲双胍组的体重指数（BMI）低于吡格列酮组（P<0.05）。与治疗前水平相比，治疗12个月后两组的血管内皮功能均有所改善（P<0.05）。治疗12个月后，二甲双胍组的内皮功能较吡格列酮组有显著改善（P<0.05）。因此，对T2DM患者给予二甲双胍和吡格列酮可能会改善胰岛素功能，降低IR的作用并改善内皮功能。在降低BMI和改善内皮功能方面，二甲双胍比吡格列酮更有效。
